Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1996-10-30
|
| pubmed:abstractText |
Bone metastases are a major cause of morbidity in breast cancer, resulting in complications that include pain, loss of mobility, pathologic fracture, and tumor-induced hypercalcemia (TIH). Inhibition of osteoclast-mediated bone destruction using bisphosphonates represents a promising new management approach.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2552-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8823335-Adult,
pubmed-meshheading:8823335-Aged,
pubmed-meshheading:8823335-Antineoplastic Agents,
pubmed-meshheading:8823335-Bone Neoplasms,
pubmed-meshheading:8823335-Breast Neoplasms,
pubmed-meshheading:8823335-Calcium,
pubmed-meshheading:8823335-Diphosphonates,
pubmed-meshheading:8823335-Female,
pubmed-meshheading:8823335-Humans,
pubmed-meshheading:8823335-Infusions, Intravenous,
pubmed-meshheading:8823335-Middle Aged
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
|
| pubmed:affiliation |
Division of Medical Oncology, St Chiara Hospital, Pisa, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|